Organisations can apply for a share of £25 million to develop new vaccines against infectious diseases
Award: Up to £2 million
Opens: 17th Oct 2016
Closes: 4th Jan 2017
This competition will support projects seeking to develop candidate vaccines and vaccine platform technologies at the preclinical stage. The aim is to enable an effective and rapid response during future outbreaks of disease. The UK Vaccine Network has identified these 12 pathogens as a priority:
All aspects of vaccine candidate development at the preclinical stage will be supported. These include, but are not limited to:
The funders are also interested in supporting ambitious multivalent candidate vaccines. These could protect against multiple strains of a single pathogen, or against multiple pathogens. For example, applicants could develop a multivalent ebola vaccine, a multivalent ebola plus marburg vaccine, or a vaccine against ebola, marburg and lassa.
This competition is wholly funded by Official Development Assistance. This means that vaccines developed as part of the competition should be appropriate for use in low and middle-income countries (LMICs) and outbreak settings. Therefore applicants should also consider:
This competition has two stages
Only projects that are supported in stage 1 will be eligible to apply for stage 2 funding.
It is expected that stage 1 of the competition will fund preclinical work. Awards made at stage 2 of the competition will fund further preclinical work, up to and including good laboratory practice toxicology/manufacturing. Stage 2 awards will also fund early clinical work, where this is feasible and appropriate.
A further launch of a vaccine development competition, focused on the clinical development of vaccines, is expected in January 2017. This is for organisations that can move more rapidly to clinical work with their candidate vaccine.